Price movement over the last 24 hours
ADMA Biologics Inc vs Seagate Technology Holdings PLC — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Seagate Technology Holdings PLC trades at $831.09 (market cap $187.26B). The key difference: Seagate Technology Holdings PLC is far larger — about 87.9× ADMA Biologics Inc's market cap, and Seagate Technology Holdings PLC pays a 0.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | STX | |
|---|---|---|
Market Cap | $2.13B | $187.26B |
Sector | Health | Technology |
52-Week High | $20.38 | $1.09K |
52-Week Low | $7.60 | $142.01 |
Enterprise Value | $2.20B | $190.29B |
Dividend Yield | — | 0.36% |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
STX trades at $827.64, up 0.91% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamental momentum, with Q1 2026 EPS of $4.10 beating expectations of $3.51, continuing a trend of earnings beats. Revenue for 2025 reached $9.10 billion with a net income margin of 21.6%, while valuation ratios like P/E of 82.38 and P/B of 179.4 reflect high growth expectations. Recent news highlights STX as a top momentum stock amid AI-driven demand, despite sector volatility.
The outlook for STX is positive, driven by robust earnings growth and AI infrastructure demand, with a consensus price target of $955.71 implying 15% upside. Risks include high debt levels, with a debt-to-asset ratio of 73.31% in 2024, and sensitivity to memory market fluctuations, as seen in recent sell-offs. Investor sentiment remains bullish among analysts, with 51% buy ratings, but technical weakness warrants caution near-term.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →